Prevenar 13

Indications

• Poisoning
• Drug overdose
• Gastrointestinal decontamination

Dosage

Children: Refer to specific guidelines for the substance involved in poisoning or overdose, as doses vary widely based on the clinical scenario.

Adults: Refer to specific guidelines for the substance involved in poisoning or overdose, as doses vary widely based on the clinical scenario.

Mechanism of action

Adsorption occurs when molecules from a liquid or gas phase adhere to the surface of a solid, forming a film. This interaction can be influenced by various forces, including van der Waals forces, hydrogen bonding, and electrostatic interactions. In the context of activated charcoal, for example, it binds to various substances in the gut, preventing their absorption into the bloodstream and facilitating their excretion.

Pharmacodynamics

The pharmacodynamic effects of adsorbed substances depend on the specific material and its intended use. In general, adsorbents can reduce the bioavailability of certain drugs and toxins by binding them within the gastrointestinal tract and thus decreasing their systemic effects. This can be particularly advantageous in cases of poisoning or overdose, where rapid removal of the substance is desired.

Pharmacokinetics

The pharmacokinetics of adsorbed substances are complex and vary significantly depending on the specific adsorbent used. For instance, activated charcoal does not undergo metabolism and is excreted unchanged in the feces. The onset of action is rapid, as the adsorption occurs immediately upon contact in the gastrointestinal tract. The duration of effect depends on the concentration of the adsorbent and the presence of the substance to be adsorbed.

Pregnancy

Adsorbed is generally considered safe during pregnancy, but it should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether adsorbed is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Dyspepsia
• Peptic ulcer disease
• Gastroesophageal reflux disease (GERD)
• Heartburn
• Diarrhea
• Mucosal irritations

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations based on the condition being treated.

Mechanism of action

Aluminum acts as an astringent, causing local shrinkage or constriction of body tissues through osmotic flow of fluids away from the area of application. This mechanism assists in reducing mucous secretions and managing conditions such as peptic ulcers and diarrhea. Additionally, it can help in drying and hardening of tissues when applied topically.

Pharmacodynamics

Aluminum-based antacids work by neutralizing gastric acid, leading to an increase in gastric pH. This action helps to alleviate symptoms associated with excess gastric acid, such as heartburn and discomfort. The astringent properties of aluminum also contribute to its therapeutic effects in managing mucosal irritations and secretions.

Pharmacokinetics

Aluminum is absorbed minimally when taken orally, with a bioavailability of about 0.1 to 0.5%. The majority of aluminum is excreted renally, and its half-life can be prolonged in individuals with renal impairment. Long-term use may lead to accumulation and potential toxicity, particularly impacting bone and neurological health.

Interactions

• aluminiumhydroxide+deferasirox: Severe (decreases exposure)
• aluminiumhydroxide+enteralfeeds: Unknown (increases risk of blocked enteral or nasogastric tubes)
• aluminiumhydroxide+roxadustat: Unknown (decreases exposure)

Pregnancy

Aluminum compounds are generally considered safe in pregnancy when used as directed. However, excessive exposure should be avoided.

Breast-feeding

Aluminum is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• aluminium hydroxide suspension
• aluminium hydroxide tablets

Indications

• Menopausal symptoms
• Vulvar and vaginal atrophy
• Prevention of osteoporosis in postmenopausal women
• Hypoestrogenism due to hypogonadism or castration

Dosage

Children: Conjugated estrogens are not typically indicated for use in the pediatric population. Refer to specialized resources for any off-label use.

Adults: Refer to the BNF for specific dosing guidelines, as doses may vary based on the indication and patient-specific factors.

Mechanism of action

Conjugated estrogens exert their effects primarily through binding to estrogen receptors, leading to the activation of estrogen-responsive genes. This binding triggers a cascade of biological responses that promote the development and maintenance of female reproductive tissues, regulation of the menstrual cycle, and other systemic effects such as bone density maintenance and modulation of cholesterol levels.

Pharmacodynamics

The pharmacodynamics of conjugated estrogens involve their role in modulating gene expression within estrogen-responsive tissues. They help to alleviate symptoms associated with menopause, such as hot flashes and vaginal dryness, and play a critical role in bone health by inhibiting osteoclast activity, thus reducing bone resorption and helping to prevent osteoporosis.

Pharmacokinetics

Following oral administration, conjugated estrogens are absorbed through the gastrointestinal tract. They undergo first-pass metabolism in the liver, which can affect their bioavailability. The half-life of conjugated estrogens varies, but they generally have a half-life of several hours. They are metabolized primarily in the liver and excreted in urine. The pharmacokinetics can be influenced by factors such as age, liver function, and concurrent medications.

Contra-indications

• Known hypersensitivity to conjugated estrogens or any of the excipients
• Estrogen-dependent neoplasms, including breast cancer
• Undiagnosed abnormal genital bleeding
• Active or past venous thromboembolic disorders
• Severe liver dysfunction or disease
• Pregnancy

Adverse effects

• Nausea
• Headache
• Breast tenderness
• Abdominal cramps
• Bloating
• Mood changes
• Increased risk of thromboembolic events
• Hypertension
• Cholestatic jaundice
• Gallbladder disease

Interactions

• Anticoagulants may have altered effects
• Certain anticonvulsants may reduce efficacy of estrogen therapy
• Rifampicin and other enzyme inducers may decrease effectiveness
• St. John's Wort may decrease hormone levels

Precautions

• Monitor patients for signs of thromboembolic disorders
• Assess risk factors for cardiovascular disease
• Evaluate liver function before and during treatment
• Consider individual patient history of breast cancer or other estrogen-sensitive conditions

Pregnancy

Conjugated estrogens are contraindicated in pregnancy due to risk of fetal harm.

Breast-feeding

Conjugated estrogens may be excreted in breast milk; use with caution in breastfeeding women.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable forms

Indications

• Prevention of pneumococcal pneumonia
• Prevention of invasive pneumococcal disease
• Prevention of meningitis caused by Streptococcus pneumoniae
• Prevention of otitis media in children

Dosage

Children: Refer to specific vaccine guidelines; typically administered as a series of doses during infancy and early childhood.

Adults: Refer to specific vaccine guidelines; typically administered as a single dose for adults, with possible revaccination based on risk factors and vaccine type.

Mechanism of action

Pneumococcal vaccines work primarily by inducing an immune response that leads to the production of specific antibodies against the polysaccharide capsule of Streptococcus pneumoniae. Upon vaccination, B cells are activated, and memory cells are formed, providing long-term immunity against future infections.

Pharmacodynamics

The efficacy of pneumococcal vaccines is related to their ability to generate an immune response. Vaccination leads to the production of immunoglobulin G (IgG) antibodies, which help opsonize the bacteria, enhancing phagocytosis by immune cells. The vaccines are effective in preventing invasive pneumococcal disease and reducing the incidence of pneumonia caused by the serotypes included in the vaccine formulation.

Pharmacokinetics

Pneumococcal vaccines do not have a pharmacokinetic profile in the traditional sense since they are biological products that induce an immune response rather than being absorbed, distributed, metabolized, and excreted like conventional drugs. The onset of immunity typically occurs within 2 to 3 weeks following vaccination.

Adverse effects

• Local reactions at the injection site
• Fever
• Fatigue
• Malaise
• Headache
• Nausea

Precautions

• Use with caution in individuals with a history of severe allergic reactions to any component of the vaccine
• Monitor for anaphylaxis in patients with known allergies

Pregnancy

The pneumococcal vaccine is generally considered safe during pregnancy, but vaccination should be discussed with a healthcare provider.

Breast-feeding

The pneumococcal vaccine is safe for breastfeeding mothers.

Storage

Store the vaccine in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Pneumococcal polysaccharide vaccine (PPSV23)
• Pneumococcal conjugate vaccine (PCV13)

Mechanism of action

Polysaccharides exert their effects through various mechanisms, often involving the modulation of immune responses. For example, certain polysaccharides can act as pathogen-associated molecular patterns (PAMPs) that are recognized by pattern recognition receptors on immune cells, leading to the activation of innate immunity. Additionally, some polysaccharides can enhance the proliferation and activation of lymphocytes, such as T-cells and B-cells, thereby influencing adaptive immune responses. Some polysaccharides also play a role in anticoagulation by inhibiting thrombin and other factors in the coagulation cascade.

Pharmacodynamics

The pharmacodynamics of polysaccharides vary widely depending on their structure and the specific biological pathways they influence. For instance, polysaccharides that act as immunomodulators can increase cytokine production, enhance phagocytosis by macrophages, and promote the differentiation of immune cells, leading to a more robust immune response. Furthermore, polysaccharides can exhibit anti-inflammatory properties by modulating the release of pro-inflammatory cytokines and chemokines. In the case of anticoagulant polysaccharides, their action may involve the binding and inhibition of specific clotting factors, thus preventing thrombus formation.

Pharmacokinetics

The pharmacokinetics of polysaccharides depend on their molecular weight, structure, and route of administration. Generally, polysaccharides are poorly absorbed in the gastrointestinal tract when taken orally due to their large size and complexity. However, certain polysaccharides are designed for parenteral administration, where they can be directly introduced into the bloodstream. Following administration, they may be metabolized by specific enzymes or by gut microbiota. The elimination half-life can vary significantly, influenced by factors such as the degree of sulfation or acetylation, which can affect their

Pregnancy

Polysaccharides are generally considered safe during pregnancy, but specific formulations should be evaluated on a case-by-case basis. Always consult a healthcare provider.

Breast-feeding

Polysaccharides are typically considered safe during breastfeeding, although individual formulations may vary. Consultation with a healthcare provider is recommended.

Storage

Polysaccharides should be stored in a cool, dry place, away from direct sunlight and moisture. Specific storage conditions may vary depending on the formulation.

Indications

• Nutritional supplementation
• Muscle repair and growth
• Immune support
• Enzyme replacement therapy
• Hormonal regulation

Dosage

Children: Refer to specific product guidelines for dosing information, as protein requirements in children vary based on age, growth stage, and health status.

Adults: Refer to specific product guidelines for dosing information, as protein requirements can vary widely based on individual needs, activity levels, and clinical conditions.

Mechanism of action

Proteins exert their effects primarily through their structure and interactions with other molecules. They can function as enzymes, hormones, and antibodies, and their action is often mediated by binding to specific receptors or substrates, leading to a change in cellular activity or function. For example, enzymes catalyze biochemical reactions, while antibodies bind to antigens to facilitate immune responses.

Pharmacodynamics

The pharmacodynamics of proteins can vary significantly depending on the specific protein being considered. Generally, the effects of proteins are dose-dependent and influenced by their concentration, affinity for targets, and duration of action. Proteins can have a wide range of biological activities, including promoting cellular repair, regulating metabolism, and modulating immune responses.

Pharmacokinetics

The pharmacokinetics of proteins includes their absorption, distribution, metabolism, and excretion (ADME). Proteins are typically digested in the gastrointestinal tract into amino acids before being absorbed into the bloodstream. Once in circulation, proteins can be distributed throughout various tissues. They may have a variable half-life based on their structure and function, and they are primarily metabolized by the liver and excreted via the kidneys. The pharmacokinetic profile can be influenced by factors such as the route of administration and the presence of other substances.

Pregnancy

Generally considered safe, but high protein intake should be monitored to avoid potential risks.

Breast-feeding

Adequate protein intake is critical for lactating women to support milk production and quality.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Identification of bacterial and viral infections
• Epidemiological studies
• Vaccination strategies
• Clinical diagnostics

Dosage

Children: Refer to specific product guidelines or clinical protocols for dosing information as it varies based on the condition and serotype involved.

Adults: Refer to specific product guidelines or clinical protocols for dosing information as it varies based on the condition and serotype involved.

Mechanism of action

Serotyping involves the use of specific antibodies that bind to surface antigens of pathogens. This binding facilitates the identification and classification of serotypes based on their immunological properties. The immune response generated by these antigens can influence the severity of infections and the effectiveness of vaccines.

Pharmacodynamics

The pharmacodynamics of serotypes are not directly related to drug action but rather to the immune response they elicit. Different serotypes can cause varying degrees of virulence and influence host immune responses differently. The effectiveness of vaccines may also vary depending on the serotype, highlighting the importance of serotyping in vaccine development and epidemiology.

Pharmacokinetics

As serotypes are classifications based on antigenic properties rather than drugs, there are no pharmacokinetic profiles associated with them. However, understanding the pharmacokinetics of vaccines targeting specific serotypes is essential for assessing their efficacy and safety.

Pregnancy

Safety during pregnancy has not been established. Use only if potential benefits justify the risks.

Breast-feeding

Caution is advised. It is unknown whether this drug is excreted in human milk.

Storage

Store in a cool, dry place, protected from light. Follow specific manufacturer's instructions for storage conditions.

Indications

• Infection diagnosis
• Vaccine development
• Epidemiological studies
• Immunology research

Dosage

Children: Refer to specific guidelines based on the serotype and associated treatment or vaccine.

Adults: Refer to specific guidelines based on the serotype and associated treatment or vaccine.

Mechanism of action

Serotypes exhibit differences in their surface antigens, which can include polysaccharides, proteins, or lipopolysaccharides. These variations affect how the immune system recognizes and responds to the pathogen. For example, certain serotypes may evade immune detection or induce a stronger immune response, influencing both disease severity and immunization strategies.

Pharmacodynamics

The pharmacodynamics of serotypes primarily involves their interaction with the immune system. The specific antigens present on the surface of a serotype determine its immunogenicity, influencing how well the immune system can recognize and mount a response against it. This can result in varied clinical outcomes, ranging from asymptomatic carriage to severe disease.

Pharmacokinetics

The pharmacokinetics of serotypes is not directly applicable as serotypes themselves are not drugs, but rather classifications of microorganisms. However, understanding the distribution, metabolism, and excretion of the pathogens associated with different serotypes can provide insights into infection dynamics and treatment responses.

Pregnancy

Safety during pregnancy has not been established for all serotypes. Consult healthcare providers for specific risks.

Breast-feeding

Consult healthcare providers regarding the safety of specific serotypes during breastfeeding.

Storage

Store according to specific guidelines for each serotype, typically in a cool, dry place away from direct sunlight.

Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Excessive dietary aluminum has been proposed to be a factor contributing to several neurological disorders in humans. Six 8-week-old female Swiss Webster mice were fed for 10 wk purified diets containing 100 (control), 500 or 1000 ug aluminum/g diet. Brain and liver lipid peroxidation was determined by evaluating the production of 2-thiobarbituric acid reactive substances in brain and liver homogenates in the presence or absence of 50 uM ferrous iron. 2-Thiobarbituric acid reactive substances production in the absence of iron in brain homogenates from mice fed the 1000 ug/g diet was higher (30%) than that in the 100 ug/g control group (3.1 vs 2.4 nmol 2-thiobarbituric acid reactive substances/mg protein). The addition of ferrous iron increased 2-thiobarbituric acid reactive substances production in brain homogenates from all 3 dietary groups. The iron induced 2-thiobarbituric acid reactive substances production was 26% higher in the 1000 ug/g brain homogenates than in the 100 ug/g group (4.9 vs 3.9 nmol 2-thiobarbituric acid reactive substances/mg protein). Brain 2-thiobarbituric acid reactive substances production in the presence and absence of iron was similar between the 100 and 500 ug/g aluminum groups. 2-Thiobarbituric acid reactive substances production in liver homogenates measured either with or without iron was similar for the 3 groups. These results show that, in mice, dietary aluminum intoxication leads to increased brain 2-thiobarbituric acid reactive substance production, suggesting that enhanced lipid peroxidation may be one possible mechanism underlying the neurological damage associated with increased tissue aluminum. Evidence is presented indicating that dementias are associated with a relative insufficiency of magnesium in the brain. Such insufficiency may be attributable to low intake or retention of magnesium; high intake of a neurotoxic metal, such as aluminum, which inhibits activity of magnesium requiring enzymes; or impaired transport of magnesium and/or enhanced transport of the neurotoxic metal into brain tissue. It is proposed that Alzheimer's disease involves a defective transport process, characterized by both an abnormally high incorporation of aluminum and an abnormally low incorporation that an altered serum protein contributes to the progression of Alzheimer's disease by having a greater affinity for aluminum than for magnesium, in contrast to the normal protein, which binds magnesium better than aluminum. The altered protein crosses the blood-brain barrier more efficiently than the normal protein and competes with the normal protein in binding to brain neurons. Binding of the altered protein to the target neurons would both facilitate aluminum uptake and impede magnesium uptake. Evidence suggests that albumin is the serum protein that is altered. Aluminum is established as a neurotoxin, although the basis for its toxicity is unknown. It recently has been shown to alter the function of the blood-brain barrier, which regulates ex